Workshop Report and Follow-Up—AAPS Workshop on Current Topics in GLP Bioanalysis: Assay Reproducibility for Incurred Samples—Implications of Crystal City Recommendations

被引:216
作者
Douglas M. Fast
Marian Kelley
C. T. Viswanathan
Jacqueline O’Shaughnessy
S. Peter King
Ajai Chaudhary
Russell Weiner
Anthony J. DeStefano
Daniel Tang
机构
[1] Pharmacokinetics,
[2] Dynamics,undefined
[3] and Metabolism,undefined
[4] Pfizer Inc.,undefined
[5] MKelley Consulting LLC,undefined
[6] Division of Scientific Investigations,undefined
[7] Office of Compliance,undefined
[8] CDER,undefined
[9] US Food and Drug Administration,undefined
[10] QPS LLC,undefined
[11] Lilly Research Laboratory,undefined
[12] Bristol-Myers-Squibb,undefined
[13] US Pharmacopeia,undefined
[14] Shanghai ChemPartner Co.,undefined
[15] LTD.,undefined
关键词
bioanalytical; confirmatory analysis; incurred sample(s); reanalysis;
D O I
10.1208/s12248-009-9100-9
中图分类号
学科分类号
摘要
The Conference Report of the 3rd AAPS/FDA Bioanalytical Workshop (Crystal City III) endorsed the concept that assay methods supporting bioanalytical data in submissions must demonstrate assay reproducibility by using incurred samples. The present Workshop was convened to provide a forum for discussion and consensus building about incurred sample assay reproducibility for both nonclinical and clinical studies. Information about current regulatory perspectives on incurred sample reanalysis (ISR) was presented, implications of ISR for both large and small molecules were discussed, and the steering committee put forth recommendations for performing ISR. These recommendations from the Workshop, along with the subsequent evolution of approaches leading to a robust ISR program, may be used by scientists performing bioanalytical assays for regulated studies to provide additional confirmation of assay reproducibility for incurred samples.
引用
收藏
页码:238 / 241
页数:3
相关论文
共 23 条
  • [1] Viswanathan CT(2007)Workshop/Conference Report—Quantitative Bioanalytical Methods Validation and Implementation: Best Practices for Chromatographic and Ligand Binding Assays AAPS Journal. 9 E30-E42
  • [2] Bansal S(2007)Confirmatory reanalysis of incurred bioanalytical samples AAPS Journal. 9 E336-E343
  • [3] Booth B(2002)A strategy for a post-method-validation use of incurred biological samples for establishing the acceptability of a liquid chromatography/tandem mass-spectrometric method for quantitation of drugs in biological samples Rapid Commun Mass Spectrom. 16 1538-1547
  • [4] DeStefano AJ(2007)Impact of differential recovery in bioanalysis: the example of bortezomib in whole blood Anal Chem. 79 1599-1603
  • [5] Rose MJ(2007)Determination of rifalazil in dog plasma by liquid–liquid extraction and LC-MS/MS: quality assessment by incurred sample analysis J Pharm Biomed Anal. 45 616-624
  • [6] Sailstad J(undefined)undefined undefined undefined undefined-undefined
  • [7] Shah VP(undefined)undefined undefined undefined undefined-undefined
  • [8] Skelly JP(undefined)undefined undefined undefined undefined-undefined
  • [9] Swann PG(undefined)undefined undefined undefined undefined-undefined
  • [10] Weiner R(undefined)undefined undefined undefined undefined-undefined